Study	Patients (N)	Treatment arms	Outcome	HR (95% CI)
Retrospective claims analysis using US Truven MarketScan data[105]	11,034	Rivaroxaban vs warfarin	Stroke/SE	0.68 (0.44–1.05)
			Ischaemic stroke	0.78 (0.48–1.30)
			Major bleeding	0.96 (0.74–1.37)
Retrospective analysis using German claims data[78]	21,845	Apixaban vs phenprocoumon	Ischaemic stroke/SE	1.03 (0.80–1.32)
			ICH	0.41 (0.22–0.74)
		Edoxaban vs phenprocoumon	Ischaemic stroke/SE	0.64 (0.31–1.30)
			ICH	–
		Rivaroxaban vs phenprocoumon	Ischaemic stroke/SE	0.83 (0.65–1.07)
			ICH	0.77 (0.49–1.21)
Retrospective claims analysis using USTruven MarketScan data[106]	24,646	Rivaroxaban vs warfarin	MACE	0.75 (0.59–0.96)
			Ischaemic stroke	0.83 (0.59–1.17)
			MALE	0.37 (0.21–0.65)
			Major bleeding	0.95 (0.79–1.15)